Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors.

@article{Kolb2009DevelopmentON,
  title={Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors.},
  author={St{\'e}phanie Kolb and Odile Mond{\'e}sert and Mary-Lor{\`e}ne Goddard and Denis Jullien and Bruno O. Villoutreix and Bernard Ducommun and Christiane Garbay and Emmanuelle Braud},
  journal={ChemMedChem},
  year={2009},
  volume={4 4},
  pages={633-48}
}
The development of CDC25 phosphatase inhibitors is an interesting approach toward new antitumor agents, as CDC25 play key roles in cell-cycle regulation and are overexpressed in numerous cancers. We previously reported a novel compound belonging to the thiazolopyrimidine family that inhibits CDC25 activity with an IC(50) value of 13 microM and displays cytotoxic properties against HeLa cells. Structural modifications were subsequently conducted on this new pharmacophore which led to a library… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…